NCT05626179View on ClinicalTrials.gov

A Study of [14C]IBI351 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 18, 2023

Primary Completion Date

March 30, 2023

Study Completion Date

May 18, 2023

Conditions
Healthy Subjects
Interventions
DRUG

[14C] IBI351

The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions

Trial Locations (1)

210029

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY